Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "resistin like beta pseudogene" (ENSG00000241777) refers to a non-functional genomic sequence with homology to resistin-like beta (RETNLB), a member of the resistin-like molecule family. Unlike the protein-coding RETNLB gene, which encodes a cytokine implicated in intestinal barrier function and immunity, the pseudogene does not produce a functional protein and is not considered a therapeutic target or involved in disease mechanisms. Its annotation as a pseudogene means it contains disrupted coding regions, frame shifts, or stop codons, preventing expression of a full-length, functional product[5][6][4]. For structured data, use **Resistin-like beta** (RETNLB or RELM-beta) if studying functional aspects, not the pseudogene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Resistin-like beta pseudogene (not protein-coding).